Brief: Moleculin Receives European Medicines Agency Approval To Expand Phase 3 Miracle Clinical Trial
12/05/2025 14:25
May 12 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO EXPAND PHASE 3 MIRACLE CLINICAL TRIAL MOLECULIN BIOTECH INC - INTERIM DATA READOUT FOR MIRACLE TRIAL EXPECTED IN H2 2025 Source text: ID:nGNX3BJCbX Further company coverage: MBRX.O
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM